company background image
DFFN

Diffusion Pharmaceuticals NasdaqCM:DFFN Stock Report

Last Price

US$6.14

Market Cap

US$12.5m

7D

2.8%

1Y

-67.4%

Updated

01 Dec, 2022

Data

Company Financials +
DFFN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

DFFN Stock Overview

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen.

Diffusion Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Diffusion Pharmaceuticals
Historical stock prices
Current Share PriceUS$6.14
52 Week HighUS$23.00
52 Week LowUS$4.64
Beta1.46
1 Month Change23.05%
3 Month Change-3.46%
1 Year Change-67.38%
3 Year Change-73.87%
5 Year Change-99.41%
Change since IPO-99.59%

Recent News & Updates

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Aug 12

Recent updates

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Feb 25
We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Nov 12
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Jun 25
We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Nov 23
Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Shareholder Returns

DFFNUS BiotechsUS Market
7D2.8%2.7%1.4%
1Y-67.4%-10.3%-16.1%

Return vs Industry: DFFN underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: DFFN underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is DFFN's price volatile compared to industry and market?
DFFN volatility
DFFN Average Weekly Movement9.9%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: DFFN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: DFFN's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200116Bob Cobuzzihttps://www.diffusionpharma.com

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body’s ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Diffusion Pharmaceuticals Inc. Fundamentals Summary

How do Diffusion Pharmaceuticals's earnings and revenue compare to its market cap?
DFFN fundamental statistics
Market CapUS$12.52m
Earnings (TTM)-US$14.99m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DFFN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$14.99m
Earnings-US$14.99m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-7.35
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did DFFN perform over the long term?

See historical performance and comparison